|
1
|
Cheung N, Mitchell P and Wong TY: Diabetic
retinopathy. Lancet. 376:124–136. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kollias AN and Ulbig MW: Diabetic
retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl
Int. 107:75–84. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Congdon NG, Friedman DS and Lietman T:
Important causes of visual impairment in the world today. JAMA.
290:2057–2060. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lin KY, Hsih WH, Lin YB, Wen CY and Chang
TJ: Update in the epidemiology, risk factors, screening, and
treatment of diabetic retinopathy. J Diabetes Investig.
12:1322–1325. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Song P, Yu J, Chan KY, Theodoratou E and
Rudan I: Prevalence, risk factors and burden of diabetic
retinopathy in China: A systematic review and meta-analysis. J Glob
Health. 8(010803)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kang Q and Yang C: Oxidative stress and
diabetic retinopathy: Molecular mechanisms, pathogenetic role and
therapeutic implications. Redox Biol. 37(101799)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tan TE and Wong TY: Diabetic retinopathy:
Looking forward to 2030. Front Endocrinol (Lausanne).
13(1077669)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tan GS, Cheung N, Simó R, Cheung GC and
Wong TY: Diabetic macular oedema. Lancet Diabetes Endocrinol.
5:143–155. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liu E, Craig JE and Burdon K: Diabetic
macular oedema: Clinical risk factors and emerging genetic
influences. Clin Exp Optom. 100:569–576. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Amoaku WM, Ghanchi F, Bailey C, Banerjee
S, Banerjee S, Downey L, Gale R, Hamilton R, Khunti K, Posner E, et
al: Diabetic retinopathy and diabetic macular oedema pathways and
management: UK consensus working group. Eye (Lond). 34 (Suppl
1):S1–S51. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Simunovic MP, Hunyor AP and Ho IV:
Vitrectomy for diabetic macular edema: A systematic review and
meta-analysis. Can J Ophthalmol. 49:188–195. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yang Z, Tan TE, Shao Y, Wong TY and Li X:
Classification of diabetic retinopathy: Past, present and future.
Front Endocrinol (Lausanne). 13(1079217)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Aiello LP and Wong JS: Role of vascular
endothelial growth factor in diabetic vascular complications.
Kidney Int Suppl. 77:S113–S119. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Antonetti DA, Klein R and Gardner TW:
Diabetic retinopathy. N Engl J Med. 366:1227–1239. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang W and Lo ACY: Diabetic retinopathy:
Pathophysiology and treatments. Int J Mol Sci.
19(1816)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wong TY, Cheung CMG, Larsen M, Sharma S
and Simó R: Diabetic retinopathy. Nat Rev Dis Primers.
2(16012)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lois N, Campbell C, Waugh N, Azuara-Blanco
A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C,
et al: Diabetic macular edema and diode subthreshold micropulse
laser: A randomized double-masked noninferiority clinical trial.
Ophthalmology. 130:14–27. 2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Everett LA and Paulus YM: Laser therapy in
the treatment of diabetic retinopathy and diabetic macular edema.
Curr Diab Rep. 21(35)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Baker CW, Glassman AR, Beaulieu WT,
Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri
CD, Melia M, et al: Effect of initial management with aflibercept
vs laser photocoagulation vs observation on vision loss among
patients with diabetic macular edema involving the center of the
macula and good visual acuity: A randomized clinical trial. JAMA.
321:1880–1894. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arrigo A, Aragona E and Bandello F:
VEGF-targeting drugs for the treatment of retinal
neovascularization in diabetic retinopathy. Ann Med. 54:1089–1111.
2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Stitt AW, Curtis TM, Chen M, Medina RJ,
McKay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simó R and
Lois N: The progress in understanding and treatment of diabetic
retinopathy. Prog Retin Eye Res. 51:156–186. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gedar Totuk OM, Kanra AY, Bromand MN,
Kilic Tezanlayan G, Ari Yaylalı S, Turkmen I and Ardagil Akcakaya
A: Effectiveness of intravitreal ranibizumab in nonvitrectomized
and vitrectomized eyes with diabetic macular edema: A two-year
retrospective analysis. J Ophthalmol. 2020(2561251)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jampol LM, Glassman AR and Sun J:
Evaluation and care of patients with diabetic retinopathy. N Engl J
Med. 382:1629–1637. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yau JWY, Rogers SL, Kawasaki R, Lamoureux
EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund
J, et al: Global prevalence and major risk factors of diabetic
retinopathy. Diabetes Care. 35:556–564. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fu P, Huang Y, Wan X, Zuo H, Yang Y, Shi R
and Huang M: Efficacy and safety of pan retinal photocoagulation
combined with intravitreal anti-VEGF agents for high-risk
proliferative diabetic retinopathy: A systematic review and
meta-analysis. Medicine (Baltimore). 102(e34856)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Figueira J, Fletcher E, Massin P, Silva R,
Bandello F, Midena E, Varano M, Sivaprasad S, Eleftheriadis H,
Menon G, et al: Ranibizumab Plus panretinal photocoagulation versus
panretinal photocoagulation alone for high-risk proliferative
diabetic retinopathy (PROTEUS study). Ophthalmology. 125:691–700.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Figueira J, Silva R, Henriques J, Caldeira
Rosa P, Laíns I, Melo P, Gonçalves Nunes S and Cunha-Vaz J:
Ranibizumab for high-risk proliferative diabetic retinopathy: An
exploratory randomized controlled trial. Ophthalmologica.
235:34–41. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rebecca , Shaikh FF and Jatoi SM:
Comparison of efficacy of combination therapy of an intravitreal
injection of bevacizumab and photocoagulation versus pan retinal
photocoagulation alone in high risk proliferative diabetic
retinopathy. Pak J Med Sci. 37:157–161. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tao Y, Jiang P, Zhao Y, Song L, Ma Y, Li Y
and Wang H: Retrospective study of aflibercept in combination
therapy for high-risk proliferative diabetic retinopathy and
diabetic maculopathy. Int Ophthalmol. 41:2157–2165. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Vujosevic S, Aldington SJ, Silva P,
Hernández C, Scanlon P, Peto T and Simó R: Screening for diabetic
retinopathy: New perspectives and challenges. Lancet Diabetes
Endocrinol. 8:337–347. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Berrocal MH and Acaba-Berrocal L: Early
pars plana vitrectomy for proliferative diabetic retinopathy:
Update and review of current literature. Curr Opin Ophthalmol.
32:203–208. 2021.PubMed/NCBI View Article : Google Scholar
|
